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RESULTS: Non-compliance is a significant problem in
managing hypercholesterolaemia. Discontinuation rates
for statins in normal practice average 30% after six
months. This results in a significant loss of therapeutic re-
sponse. In the EXCEL study (lovastatin), a 41.3% reduc-
tion in LDL cholesterol was observed in those patients
who reported taking all their tablets. This compared with
a 26.6% reduction in those taking 80% of their tablets. In
a primary-care setting, the discontinuation rate for prava-
statin was 24% after two years. The reduction in LDL
cholesterol was 6% compared to 26% in those continuing
treatment. This results in a change in cost-effectiveness
from £376 to £1754 per % LDL reduction per year.
CONCLUSIONS: Noncompliance is an important factor
when assessing a drug’s effectiveness in clinical practice.
Tables comparing the cost-effectiveness of statins are of-
ten found in the medical literature, but rarely do they ac-
count for noncompliance. The present study illustrates
the need to account for the impact of noncompliance in
pharmacoeconomic evaluations.
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OBJECTIVE: Patients with hypertension are often non-
compliant with their medication. A study was conducted
in a usual clinical practice setting in patients with essen-
tial hypertension to improve medication compliance by
modifying behavior.
METHODS: The trial was designed as a randomized,
multi-center, open-label, two-arm study in patients with
essential hypertension. Four thousand eight hundred
sixty four patients recruited from general practice settings
were randomized to receive the angiotensin-receptor
blocker irbesartan with (intervention group) or without
(non-intervention group) a behavioral modification pro-
gram (Avapromise), which was based on a model of
change, and followed up for 12 months. Randomization
to Avapromise was done by site (recruiting physicians’
office) such that all the patients within one site were ran-
domized to the same treatment regimen to avoid contam-
ination and to minimize investigator bias. Patients were
sub-grouped based on their stage of change in the behav-
ioral change continuum, and the intervention was tai-
lored to address the needs of the particular sub-group.
Primary efficacy measure was rate and time to discontin-
uation with irbesartan.
RESULTS: At the end of the study the total number of
patient discontinuations was 1240 (25% of 4864). Of
these, 611 (25.4%, 95% CI: 23.7–27.2) occurred in the
intervention group and 629 (25.5%, 95% CI: 23.8–27.3)
occurred in the non-intervention group. This resulted in a
difference of 0.1% (2.6 to 2.3) between the two groups
(p  0.94). The time to discontinuation was not different
between the groups (p  0.87). The extrapolated rate of
discontinuation estimated from the Kaplan-Meier curve
was also not different between the groups (intervention:
23.1%, 95% CI: 21.3–24.8; non-intervention: 23.5%,
95% CI: 21.8–25.3).
CONCLUSION: This behavioral modification interven-
tion based on a model of change was not effective in in-
creasing compliance rates in patients with essential hy-
pertension in this setting.
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OBJECTIVE: The development of low-molecular-weight
heparins (LMWHs) as an antithrombin therapy for the
management of acute coronary syndromes was prompted
by the shortcomings of unfractionated heparin (UFH), the
standard therapy. LMWHs, and especially the most widely
used enoxaparin, offer the advantages of a stable and pre-
dictable anticoagulant response to a given dose, eliminat-
ing the need for haematologic monitoring, and much sim-
pler administration via the subcutaneous route. However,
enoxaparin should achieve improved clinical effectiveness
and demonstrate economic attractiveness. The present re-
view is an appraisal of the relative costs and benefits of
enoxaparin versus UFH in acute cardiology.
METHODS: A growing number of papers have been ad-
dressing these questions during the last five years. Most
of them are based on two worldwide multi-center, dou-
ble-blind, randomized controlled trials, TIMI 11B and
ESSENCE, involving patients with unstable angina/
non-Q wave myocardial infarction. Efficiency was evalu-
ated prospectively over the first 30 days of follow-up and
retrospectively after one year of follow up, using cost-ef-
fectiveness approach. Only direct costs were measured.
RESULTS: Enoxaparin was shown to be a dominant
strategy. It clearly improved efficacy and tolerability ver-
sus UFH, providing an absolute risk reduction of death,
myocardial infarction and recurrent angina of 3.7% to
3.5% at more or less short term. Average cost per patient
was significantly lower due to reduced frequency of diag-
nostic catheterization, revascularization procedures, an-
giography, coronary angioplasty and shorter length of
hospital stay over the first 30 days. Cost reduction arose,
on the long term, from less rehospitalizations and revas-
cularizations. Moreover, those reductions were probably
underestimated as indirect costs were not considered.
